Inmune Bio (INMB) Current Assets (2017 - 2025)
Inmune Bio (INMB) has disclosed Current Assets for 9 consecutive years, with $29.9 million as the latest value for Q4 2025.
- Quarterly Current Assets rose 31.88% to $29.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.9 million through Dec 2025, up 31.88% year-over-year, with the annual reading at $29.9 million for FY2025, 31.88% up from the prior year.
- Current Assets hit $29.9 million in Q4 2025 for Inmune Bio, down from $30.7 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $90.9 million in Q3 2021 to a low of $21.0 million in Q1 2025.
- Historically, Current Assets has averaged $49.1 million across 5 years, with a median of $44.8 million in 2021.
- Biggest five-year swings in Current Assets: surged 604.93% in 2021 and later plummeted 47.57% in 2024.
- Year by year, Current Assets stood at $82.6 million in 2021, then decreased by 21.71% to $64.7 million in 2022, then crashed by 38.24% to $39.9 million in 2023, then crashed by 43.26% to $22.7 million in 2024, then skyrocketed by 31.88% to $29.9 million in 2025.
- Business Quant data shows Current Assets for INMB at $29.9 million in Q4 2025, $30.7 million in Q3 2025, and $36.0 million in Q2 2025.